| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 根据贵州省人民政府黔府函[2001]661 号文《省人民政府关于同意贵阳新天药业有限责任公司变更设立贵阳新天药业股份有限公司的批复》，本公司以截至2001 年8 月31 日经深圳大华天诚会计师事务所审计出具的《审计报告》（深华[2001]审字第398 号）审计的账面净资产40,573,340.31 元，按整数4,057 万元1:1折为4,057 万股，余额3,340.31 元计入资本公积，整体变更设立为贵阳新天药业股份有限公司，并于2001 年12 月30 日取得注册号为5200001204533 的《企业法人营业执照》。 发行人是一家集科研、生产、销售为一体的现代化中成药制药企业，主要从事泌尿系统疾病类、妇科类及其他病因复杂类疾病用药的中成药产品研究开发、生产与销售。拥有通过GMP 认证的硬胶囊剂、凝胶剂、合剂、颗粒剂、片剂五个剂型生产线。公司拥有国家医保目录品种26 个、国家基本药物目录品种10个、非处方药（OTC）品种21 个、独家品种13 个。公司目前主要产品为宁泌泰胶囊、坤泰胶囊、苦参凝胶、夏枯草口服液。公司构建了以配方和工艺专利为核心，以剂型专利和质量标准为辅的多层级知识产权保护体系，多途径延长公司独家专利品种的生命周期，保持市场竞争力。 | ||||||||||||||||||||||||
| Main Business | 中成药新药集研发、生产及销售。 | ||||||||||||||||||||||||
| Legal Representative | 董大伦 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 王光平 | ||||||||||||||||||||||||
| Solicitors | 北京德恒律师事务所 | ||||||||||||||||||||||||
| Auditors | 信永中和会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0851-86298482 | ||||||||||||||||||||||||
| Fax No | 0851-86298482 | ||||||||||||||||||||||||
| Website | www.gyxtyy.com | ||||||||||||||||||||||||
| 002873@xtyyoa.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 19/05/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.349 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.070 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 4.722 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.352B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |